New drug cocktail aims to outsmart lung cancer in major trial
NCT ID NCT07183189
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether adding an experimental drug called SHR-A2009 to the standard targeted therapy aumolertinib works better than aumolertinib alone for people with advanced non-small cell lung cancer that has an EGFR mutation. About 576 participants who have not had prior treatment for their advanced cancer will be randomly assigned to one of the two groups. The main goal is to see if the combination delays cancer growth longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A2009 (an experimental drug) combined with aumolertinib (a targeted therapy pill)
- What this could lead to
- If successful, this combination could become a new first-line treatment option for people with advanced EGFR-mutant lung cancer, potentially delaying disease progression longer than current standard therapy.
- What could go wrong
- This is an early-phase 3 trial, so results are not yet known. The combination may cause more side effects than aumolertinib alone, and there is no guarantee it will improve survival or quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?